BOSTON MEDICAL CENTER
- Type
- Teaching hospital
- Where
- BOSTON, MA
- Medicare CCN
- 220031
- Received
- $5,097,680 in 510 records, 2023 ($804,688 general, $4,292,992 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Boston Medical Center Corporation Fuzzy (name and state)
- Business registration: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Business registration: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Business registration: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Business registration: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Nonprofit contractor: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Plan sponsor: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Nonprofit: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Patent assignee: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Trademark owner: Boston Medical Center Corporation Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2023 | General payment | 83 | $804,688 |
| 2023 | Research payment | 427 | $4,292,992 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 427 | $4,292,992 |
| Grant | 9 | $555,827 |
| Education | 41 | $177,837 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 13 | $64,996 |
| Debt forgiveness | 3 | $3,602 |
| Charitable Contribution | 15 | $1,384 |
| Consulting Fee | 1 | $541 |
| Space rental or facility fees (teaching hospital only) | 1 | $500 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2023-12-31 | Gilead Sciences, Inc. | $291,677 | Grant | Cash or cash equivalent | 2023 | ||
| 2023-12-31 | Merck Sharp & Dohme LLC | $28,678 | Research payment | In-kind items and services | GARDASIL 9 Biological, VACCINE | An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9vHPV Vaccination 2-dose Regimen over a Fo | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $28,436 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2023 |
| 2023-12-31 | RedDress LTD | $18,199 | Research payment | Cash or cash equivalent | A Multi-Center, Prospective, Randomized, Controlled, Trial, Comparing the Safety and Efficacy of ActiGraft Pro to Standa | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $14,843 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $10,697 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2023 |
| 2023-12-31 | KARL STORZ Endoscopy-America | $4,286 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-12-31 | Stryker Corporation | $3,026 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-12-31 | Philips North America LLC | $3,000 | Research payment | In-kind items and services | (6260) Ingenia 3 0T R5 Device, Medical Device | TRUST and ASE for Global Blood Therapeutics Voxelotor Trial | 2023 |
| 2023-12-31 | KARL STORZ Endoscopy-America | $2,591 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-12-31 | KARL STORZ Endoscopy-America | $2,039 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-12-31 | KARL STORZ Endoscopy-America | $2,039 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-12-31 | Philips North America LLC | $1,200 | Research payment | In-kind items and services | (6260) Ingenia 3 0T R5 Device, Medical Device | TRUST and ASE for Global Blood Therapeutics Voxelotor Trial | 2023 |
| 2023-12-31 | KARL STORZ Endoscopy-America | $916 | Education | In-kind items and services | 2023 | ||
| 2023-12-31 | KARL STORZ Endoscopy-America | $880 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-12-31 | KARL STORZ Endoscopy-America | $838 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-12-31 | KARL STORZ Endoscopy-America | $730 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-12-31 | KARL STORZ Endoscopy-America | $730 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-12-31 | KARL STORZ Endoscopy-America | $730 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-12-31 | KARL STORZ Endoscopy-America | $730 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-12-31 | ABBVIE INC. | $500 | Research payment | In-kind items and services | Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Sco | 2023 | |
| 2023-12-31 | ABBVIE INC. | $500 | Research payment | In-kind items and services | Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Sco | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $435 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2023 |
| 2023-12-31 | KARL STORZ Endoscopy-America | $423 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-12-31 | KARL STORZ Endoscopy-America | $283 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-12-31 | KARL STORZ Endoscopy-America | $213 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-12-31 | KARL STORZ Endoscopy-America | $186 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-12-31 | KARL STORZ Endoscopy-America | $154 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-12-31 | KARL STORZ Endoscopy-America | $136 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-12-31 | KARL STORZ Endoscopy-America | $120 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-12-31 | KARL STORZ Endoscopy-America | $60 | Education | In-kind items and services | 2023 | ||
| 2023-12-31 | KARL STORZ Endoscopy-America | $55 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-12-30 | PFIZER INC. | $6,276 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2023 |
| 2023-12-26 | Novo Nordisk AS | $23 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2023 |
| 2023-12-22 | PFIZER INC. | $6,605 | Research payment | Cash or cash equivalent | PAXLOVID Drug, INFECTIOUS DISEASES | A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL | 2023 |
| 2023-12-22 | Indivior Inc. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUBLOCADE Drug, OUD | 2023 | |
| 2023-12-21 | Intercept Pharma Europe Ltd. | $2,197 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2023 |
| 2023-12-21 | Intercept Pharma Europe Ltd. | $360 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2023 |
| 2023-12-18 | Immedica Pharma US, Inc. | $9,179 | Research payment | Cash or cash equivalent | A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous Ganaxolone in St | 2023 | |
| 2023-12-18 | Janssen Research & Development, LLC | $238 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo | 2023 |
| 2023-12-11 | KARL STORZ Endoscopy-America | $25,922 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-12-11 | KARL STORZ Endoscopy-America | $2,165 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-12-07 | Novo Nordisk AS | $23 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2023 |
| 2023-12-05 | KARL STORZ Endoscopy-America | $1,509 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-12-04 | KARL STORZ Endoscopy-America | $1,372 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-12-04 | KARL STORZ Endoscopy-America | $476 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-12-04 | PFIZER INC. | $403 | Research payment | In-kind items and services | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2023 | |
| 2023-12-02 | PFIZER INC. | $27,202 | Research payment | Cash or cash equivalent | PAXLOVID Drug, INFECTIOUS DISEASES | A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL | 2023 |
| 2023-12-01 | Organon Llc | $989 | Research payment | Cash or cash equivalent | Efficacy and Safety of Nexplanon 36 to 60 Months Post Insertion | 2023 | |
| 2023-11-30 | Mannkind Corporation | $8,742 | Research payment | Cash or cash equivalent | AFREZZA Drug, DIABETES MEDICINE | INHALE-3 | 2023 |
| 2023-11-30 | KARL STORZ Endoscopy-America | $3,495 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-11-30 | KARL STORZ Endoscopy-America | $3,280 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-11-30 | KARL STORZ Endoscopy-America | $3,126 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-11-30 | KARL STORZ Endoscopy-America | $2,876 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-11-30 | KARL STORZ Endoscopy-America | $2,763 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-11-30 | KARL STORZ Endoscopy-America | $2,665 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-11-30 | KARL STORZ Endoscopy-America | $2,098 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-11-30 | KARL STORZ Endoscopy-America | $782 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-11-30 | KARL STORZ Endoscopy-America | $270 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-11-30 | PFIZER INC. | $118 | Research payment | In-kind items and services | PAXLOVID Drug, INFECTIOUS DISEASES | A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL | 2023 |
| 2023-11-30 | KARL STORZ Endoscopy-America | $23 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-11-28 | Indivior Inc. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUBLOCADE Drug, OUD | 2023 | |
| 2023-11-28 | KARL STORZ Endoscopy-America | $1,980 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-11-28 | KARL STORZ Endoscopy-America | $1,938 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-11-28 | KARL STORZ Endoscopy-America | $1,769 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-11-28 | GlaxoSmithKline, LLC. | $1,300 | Research payment | Cash or cash equivalent | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | 2023 | |
| 2023-11-28 | KARL STORZ Endoscopy-America | $180 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-11-27 | Eli Lilly and Company | $222,675 | Research payment | Cash or cash equivalent | 2023 | ||
| 2023-11-27 | Novo Nordisk AS | $2,991 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2023 |
| 2023-11-27 | Novo Nordisk AS | $375 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2023 |
| 2023-11-24 | Janssen Research & Development, LLC | $44,667 | Research payment | Cash or cash equivalent | TECVAYLI Biological, Oncology | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Car | 2023 |
| 2023-11-23 | PFIZER INC. | $715 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2023 |
| 2023-11-22 | Intercept Pharma Europe Ltd. | $812 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2023 |
| 2023-11-21 | KARL STORZ Endoscopy-America | $5,991 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2023 | |
| 2023-11-17 | Janssen Research & Development, LLC | $6,350 | Research payment | Cash or cash equivalent | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E | 2023 | |
| 2023-11-17 | Takeda Pharmaceuticals U.S.A., Inc. | $1,300 | Research payment | Cash or cash equivalent | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF TAK-079 | 2023 | |
| 2023-11-15 | E.R. Squibb & Sons, L.L.C. | $169,545 | Research payment | Cash or cash equivalent | Characterization of combined DGK | 2023 | |
| 2023-11-15 | PFIZER INC. | $14,560 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2023 |
| 2023-11-15 | AstraZeneca Pharmaceuticals LP | $5,725 | Research payment | Cash or cash equivalent | A Phase 2b3 Randomized, Double blind, Placebo controlled Study to Evaluate the Safety and Efficacy of Cotadutide in Part | 2023 | |
| 2023-11-15 | PFIZER INC. | $1,105 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-11-14 | Merck Healthcare KGaA | $1,300 | Research payment | Cash or cash equivalent | TEPMETKO Drug, Oncology | A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic no | 2023 |
| 2023-11-14 | ABBVIE INC. | $1,137 | Research payment | Cash or cash equivalent | Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Sco | 2023 | |
| 2023-11-11 | E.R. Squibb & Sons, L.L.C. | $134 | Research payment | Cash or cash equivalent | CAMZYOS Drug, Virology | A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Non-obst | 2023 |
| 2023-11-10 | Mannkind Corporation | $33,599 | Research payment | Cash or cash equivalent | AFREZZA Drug, DIABETES MEDICINE | INHALE-3 | 2023 |
| 2023-11-09 | PFIZER INC. | $1,925 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2023 |
| 2023-11-08 | Merck Sharp & Dohme LLC | $264,999 | Research payment | Cash or cash equivalent | GARDASIL 9 Biological, VACCINE | An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9vHPV Vaccination 2-dose Regimen over a Fo | 2023 |
| 2023-11-07 | Eli Lilly and Company | $57,385 | Research payment | Cash or cash equivalent | A STUDY OF LY3540378 IN PARTICIPANTS WITH WORSENING CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) | 2023 | |
| 2023-11-06 | Janssen Research & Development, LLC | $238 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo | 2023 |
| 2023-11-02 | Intercept Pharma Europe Ltd. | $5,411 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2023 |
| 2023-11-02 | Intercept Pharma Europe Ltd. | $897 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2023 |
| 2023-11-02 | Novo Nordisk AS | $23 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2023 |
| 2023-11-01 | INSTYLLA, INC. | $8,720 | Research payment | Cash or cash equivalent | INSTYLLA MICROCATHETER Device, Liquid Embolics for Interventional Radiology | Randomized Multi-Center, Subject and Evaluator Blinded, Parallel-Group Study to Evaluate the Safety and Effectiveness of | 2023 |
| 2023-10-30 | PFIZER INC. | $137,066 | Research payment | Cash or cash equivalent | ULTRASTRUCTURAL ANALYSIS OF PODOCYTE FOOT PROCESS WIDTH AND OTHER HISTOLOGICAL ANALYSES OF KIDNEY DISEASE SAMPLES AND BI | 2023 | |
| 2023-10-30 | Acera Surgical, Inc. | $56,368 | Research payment | Cash or cash equivalent | Restrata Wound Matrix Device, Wound Care | Assessment of Wound Closure Comparing Synthetic Hybrid- Scale Fiber Matrix with Lyophilized Acellular Fish Skin in Treat | 2023 |
| 2023-10-30 | Acera Surgical, Inc. | $2,430 | Research payment | Cash or cash equivalent | Restrata Wound Matrix Device, Wound Care | Assessment of Wound Closure Comparing Synthetic Hybrid- Scale Fiber Matrix with Lyophilized Acellular Fish Skin in Treat | 2023 |
| 2023-10-27 | Indivior Inc. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUBLOCADE Drug, OUD | 2023 | |
| 2023-10-27 | Indivior Inc. | $4,998 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUBLOCADE Drug, OUD | 2023 | |
| 2023-10-26 | PFIZER INC. | $345 | Research payment | In-kind items and services | COMIRNATY Biological, VACCINES | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC | 2023 |
| 2023-10-23 | Novo Nordisk AS | $2,012 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2023 |
| 2023-10-19 | Intercept Pharma Europe Ltd. | $35,746 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2023 |
| 2023-10-19 | Intercept Pharma Europe Ltd. | $2,730 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2023 |
| 2023-10-19 | PFIZER INC. | $1,300 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2023 |
| 2023-10-18 | KLS-Martin L.P. | $3,750 | Grant | Cash or cash equivalent | 2023 | ||
| 2023-10-18 | PFIZER INC. | $1,434 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2023 |
| 2023-10-17 | COLOPLAST CORP | $125,000 | Grant | Cash or cash equivalent | Titan Device, Men's Health | 2023 | |
| 2023-10-17 | GlaxoSmithKline, LLC. | $13,000 | Research payment | Cash or cash equivalent | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | 2023 | |
| 2023-10-17 | GlaxoSmithKline, LLC. | $5,392 | Research payment | Cash or cash equivalent | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | 2023 | |
| 2023-10-17 | GlaxoSmithKline, LLC. | $4,225 | Research payment | Cash or cash equivalent | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | 2023 | |
| 2023-10-17 | GlaxoSmithKline, LLC. | $3,250 | Research payment | Cash or cash equivalent | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | 2023 | |
| 2023-10-17 | GlaxoSmithKline, LLC. | $1,500 | Research payment | Cash or cash equivalent | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | 2023 | |
| 2023-10-16 | Janssen Research & Development, LLC | $26,067 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2023 | |
| 2023-10-10 | Abbott Laboratories | $46 | Research payment | In-kind items and services | FreeStyle Libre 2 Device, Diabetes Care | Evaluation of Flash Continuous Glucose Monitoring to Reduce Hyperglycemia in People with T2 Diabetes | 2023 |
| 2023-10-05 | Novo Nordisk AS | $69 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2023 |
| 2023-10-05 | Novo Nordisk AS | $60 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2023 |
| 2023-10-05 | Novo Nordisk AS | $32 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2023 |
| 2023-10-05 | Novo Nordisk AS | $15 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2023 |
| 2023-10-05 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2023 |
| 2023-10-04 | Merck Sharp & Dohme LLC | $111,919 | Research payment | Cash or cash equivalent | ISENTRESS Drug, INFECTIOUS DISEASE | Intensified antiretroviral therapy with raltegravir in acute HIV infection to limit establishment of the viral reservoir | 2023 |
| 2023-10-02 | Janssen Research & Development, LLC | $714 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo | 2023 |
| 2023-09-26 | Novo Nordisk AS | $23 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2023 |
| 2023-09-26 | Novo Nordisk AS | $10 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2023 |
| 2023-09-23 | PFIZER INC. | $717 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2023 |
| 2023-09-22 | Novo Nordisk AS | $426 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2023 |
| 2023-09-22 | Novo Nordisk AS | $375 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2023 |
| 2023-09-15 | PFIZER INC. | $1,034 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC | 2023 |
| 2023-09-13 | G1 Therapeutics, Inc. | $49,211 | Research payment | Cash or cash equivalent | COSELA Drug, Oncology | G1T28-207 | 2023 |
| 2023-09-11 | PFIZER INC. | $23,642 | Research payment | Cash or cash equivalent | MEASURING PODOCYTE URINARY BIOMARKERS ACROSS RENAL DISORDERS | 2023 | |
| 2023-09-11 | Agios Pharmaceuticals, Inc. | $1,625 | Research payment | Cash or cash equivalent | PYRUKYND Drug, Genetically Defined Disease | A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Voluntee | 2023 |
| 2023-09-11 | Janssen Research & Development, LLC | $476 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo | 2023 |
| 2023-09-11 | Agios Pharmaceuticals, Inc. | $65 | Research payment | Cash or cash equivalent | PYRUKYND Drug, Genetically Defined Disease | A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Voluntee | 2023 |
| 2023-09-07 | PFIZER INC. | $30,362 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2023 |
| 2023-09-02 | PFIZER INC. | $8,484 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2023 |
| 2023-09-01 | Novo Nordisk AS | $23 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2023 |
| 2023-09-01 | Eli Lilly and Company | $18 | Research payment | In-kind items and services | A STUDY OF LY3540378 IN PARTICIPANTS WITH WORSENING CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) | 2023 | |
| 2023-09-01 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2023 |
| 2023-08-31 | Route 92 Medical, Inc. | $28,770 | Research payment | Cash or cash equivalent | HIPOINT 088 Device, NEURO ASPIRATION | SUMMIT MAX | 2023 |
| 2023-08-31 | QIAGEN, LLC | $442 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-08-31 | Abbott Laboratories | $90 | Research payment | In-kind items and services | FreeStyle Libre 2 Device, Diabetes Care | Evaluation of Flash Continuous Glucose Monitoring to Reduce Hyperglycemia in People with T2 Diabetes | 2023 |
| 2023-08-30 | Intercept Pharma Europe Ltd. | $17,290 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2023 |
| 2023-08-30 | Medline Industries LP | $2,600 | Research payment | Cash or cash equivalent | 422299 Device, THIS IS MATERIAL NUMBER SQU422299BX | OPTICELL VS. AQUACEL | 2023 |
| 2023-08-30 | PFIZER INC. | $650 | Research payment | Cash or cash equivalent | PAXLOVID Drug, INFECTIOUS DISEASES | A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL | 2023 |
| 2023-08-24 | Intercept Pharma Europe Ltd. | $11,764 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2023 |
| 2023-08-24 | PFIZER INC. | $717 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2023 |
| 2023-08-23 | Merck Sharp & Dohme LLC | $13,586 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2023 |
| 2023-08-23 | Indivior Inc. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUBLOCADE Drug, OUD | 2023 | |
| 2023-08-22 | E.R. Squibb & Sons, L.L.C. | $49,958 | Research payment | Cash or cash equivalent | Multidimensional IO markers of Response and Resistance To Checkpoint Inhibition in Cancer Patients | 2023 | |
| 2023-08-22 | PFIZER INC. | $942 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-08-18 | Acrotech Biopharma Inc. | $11,660 | Research payment | Cash or cash equivalent | EVOMELA Drug, ONCOLOGY | IIS-MEL-003 | 2023 |
| 2023-08-18 | Novo Nordisk AS | $2,565 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2023 |
| 2023-08-18 | Novo Nordisk AS | $516 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2023 |
| 2023-08-17 | PFIZER INC. | $3,770 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-08-16 | Indivior Inc. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Sublocade Drug, Opioid Use Disorder | 2023 | |
| 2023-08-16 | Janssen Research & Development, LLC | $3,900 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2023 |
| 2023-08-16 | Janssen Research & Development, LLC | $492 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2023 |
| 2023-08-14 | PFIZER INC. | $137,066 | Research payment | Cash or cash equivalent | ULTRASTRUCTURAL ANALYSIS OF PODOCYTE FOOT PROCESS WIDTH AND OTHER HISTOLOGICAL ANALYSES OF KIDNEY DISEASE SAMPLES AND BI | 2023 | |
| 2023-08-11 | Janssen Research & Development, LLC | $18,648 | Research payment | Cash or cash equivalent | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E | 2023 | |
| 2023-08-11 | Janssen Research & Development, LLC | $11,250 | Research payment | Cash or cash equivalent | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E | 2023 | |
| 2023-08-11 | CSL Behring | $10,400 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2023 |
| 2023-08-11 | CSL Behring | $4,225 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2023 |
| 2023-08-11 | CSL Behring | $3,250 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2023 |
| 2023-08-11 | CSL Behring | $1,500 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2023 |
| 2023-08-10 | Janssen Research & Development, LLC | $238 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo | 2023 |
| 2023-08-09 | PFIZER INC. | $2,892 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-08-08 | Immedica Pharma US, Inc. | $1,905 | Research payment | In-kind items and services | A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous Ganaxolone in St | 2023 | |
| 2023-08-03 | Mannkind Corporation | $20,345 | Research payment | Cash or cash equivalent | AFREZZA Drug, DIABETES MEDICINE | INHALE-3 | 2023 |
| 2023-08-03 | Intercept Pharma Europe Ltd. | $2,926 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2023 |
| 2023-08-03 | ABBVIE INC. | $2,600 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexa | 2023 |
| 2023-08-03 | Medline Industries LP | $1,911 | Research payment | Cash or cash equivalent | 422299 Device, THIS IS MATERIAL NUMBER SQU422299BX | OPTICELL VS. AQUACEL | 2023 |
| 2023-08-02 | Agios Pharmaceuticals, Inc. | $4,399 | Research payment | Cash or cash equivalent | PYRUKYND Drug, Genetically Defined Disease | A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Voluntee | 2023 |
| 2023-08-02 | Agios Pharmaceuticals, Inc. | $4,066 | Research payment | Cash or cash equivalent | PYRUKYND Drug, Genetically Defined Disease | A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Voluntee | 2023 |
| 2023-08-02 | Agios Pharmaceuticals, Inc. | $3,987 | Research payment | Cash or cash equivalent | PYRUKYND Drug, Genetically Defined Disease | A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Voluntee | 2023 |
| 2023-08-02 | Agios Pharmaceuticals, Inc. | $2,972 | Research payment | Cash or cash equivalent | PYRUKYND Drug, Genetically Defined Disease | A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Voluntee | 2023 |
| 2023-08-02 | Agios Pharmaceuticals, Inc. | $2,632 | Research payment | Cash or cash equivalent | PYRUKYND Drug, Genetically Defined Disease | A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Voluntee | 2023 |
| 2023-08-02 | Agios Pharmaceuticals, Inc. | $2,329 | Research payment | Cash or cash equivalent | PYRUKYND Drug, Genetically Defined Disease | A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Voluntee | 2023 |
| 2023-08-02 | Agios Pharmaceuticals, Inc. | $2,329 | Research payment | Cash or cash equivalent | PYRUKYND Drug, Genetically Defined Disease | A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Voluntee | 2023 |
| 2023-08-02 | Agios Pharmaceuticals, Inc. | $2,286 | Research payment | Cash or cash equivalent | PYRUKYND Drug, Genetically Defined Disease | A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Voluntee | 2023 |
| 2023-08-02 | Agios Pharmaceuticals, Inc. | $2,244 | Research payment | Cash or cash equivalent | PYRUKYND Drug, Genetically Defined Disease | A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Voluntee | 2023 |
| 2023-08-02 | Agios Pharmaceuticals, Inc. | $1,689 | Research payment | Cash or cash equivalent | PYRUKYND Drug, Genetically Defined Disease | A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Voluntee | 2023 |
| 2023-08-02 | Agios Pharmaceuticals, Inc. | $1,689 | Research payment | Cash or cash equivalent | PYRUKYND Drug, Genetically Defined Disease | A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Voluntee | 2023 |
| 2023-08-02 | PFIZER INC. | $1,225 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC | 2023 |
| 2023-07-31 | Novo Nordisk AS | $3,598 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2023 |
| 2023-07-28 | Janssen Research & Development, LLC | $3,191 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2023 |
| 2023-07-28 | Janssen Research & Development, LLC | $3,184 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2023 |
| 2023-07-28 | Janssen Research & Development, LLC | $3,158 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2023 |
| 2023-07-28 | Janssen Research & Development, LLC | $3,070 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2023 |
| 2023-07-28 | Janssen Research & Development, LLC | $1,933 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2023 |
| 2023-07-28 | Janssen Research & Development, LLC | $1,933 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2023 |
| 2023-07-28 | Janssen Research & Development, LLC | $1,933 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2023 |
| 2023-07-28 | Janssen Research & Development, LLC | $1,060 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2023 |
| 2023-07-28 | Janssen Research & Development, LLC | $1,060 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2023 |
| 2023-07-28 | Janssen Research & Development, LLC | $1,060 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2023 |
| 2023-07-28 | Janssen Research & Development, LLC | $1,060 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2023 |
| 2023-07-28 | Janssen Research & Development, LLC | $934 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2023 |
| 2023-07-28 | Janssen Research & Development, LLC | $827 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2023 |
| 2023-07-28 | Janssen Research & Development, LLC | $827 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2023 |
| 2023-07-28 | Janssen Research & Development, LLC | $234 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2023 |
| 2023-07-28 | Janssen Research & Development, LLC | $234 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2023 |
| 2023-07-28 | Janssen Research & Development, LLC | $234 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2023 |
| 2023-07-28 | Janssen Research & Development, LLC | $234 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2023 |
| 2023-07-28 | Janssen Research & Development, LLC | $234 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2023 |
The latest 200 records of 510.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Boston, MA, county Suffolk County, MA, state Massachusetts; placed by its city name.
| Measure | Place (city or town) Boston, MA | County Suffolk County, MA | State Massachusetts |
|---|---|---|---|
| Population B01003 | 666,442 | 785,121 | 7,044,056 |
| Population, 2020 census P1 | 675,647 | 797,936 | 7,029,917 |
| Median age B01002 | 33.3 | 33.9 | 40.0 |
| Under 18 B01001 | 15.1% | 16.0% | 19.4% |
| 65 and over B01001 | 13.0% | 13.3% | 17.9% |
| Households B11001 | 283,374 | 327,167 | 2,785,042 |
| Foreign born B05002 | 27.8% | 29.8% | 18.0% |
| Median household income B19013 | $97,344 | $95,631 | $103,960 |
| Median family income B19113 | $116,436 | $112,072 | $131,675 |
| Per capita income B19301 | $61,698 | $58,636 | $57,897 |
| Poverty rate B17001 | 16.6% | 16.2% | 10.0% |
| Unemployment rate B23025 | 6.1% | 6.3% | 5.2% |
| Civilian labor force B23025 | 402,354 | 468,636 | 3,911,446 |
| Mean commute (minutes) B08013 | 30.3 | 30.9 | 29.1 |
| Bachelor's degree or higher B15003 | 54.9% | 50.6% | 47.3% |
| Housing units B25001 | 310,625 | 357,290 | 3,030,406 |
| Owner-occupied B25003 | 35.7% | 36.5% | 62.5% |
| Renters B25003 | 64.3% | 63.5% | 37.5% |
| Median home value B25077 | $731,700 | $705,800 | $562,100 |
| Median gross rent B25064 | $2,147 | $2,129 | $1,762 |
| White, not Hispanic B03002 | 44.1% | 43.6% | 66.6% |
| Black B03002 | 19.3% | 17.1% | 6.4% |
| Hispanic or Latino B03002 | 19.3% | 23.2% | 13.3% |
| Asian B03002 | 10.3% | 9.2% | 7.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Boston, MA.
Comments